Zentera Therapeutics, Inc. is a Shanghai-based clinical-stage biopharmaceutical company focused on developing cancer therapeutics. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), one of the key strategic partners of Zentera, has licensed innovative assets and R&D technologies to Zentera. The Company is also supported financially by world-leading venture capitalists, including OrbiMed Asia and Tybourne Capital Management, that have in-depth understandings of China's clinical and commercial markets. Establishing Zentera was an important milestone for Zentalis, as it enabled the advancement of Zentalis’ oncology R&D strategy into the world's second largest pharmaceutical market.


"Establishing Zentera was an important milestone for Zentalis, as it enabled the advancement of Zentalis' oncology R&D strategy into the world's second largest pharmaceutical market."

—— CEO Anthony Sun M.D.


Since its creation in 2020, Zentera has been cultivating an experienced and efficient team. We collaborate with major hospitals to carry out clinical research in a precise, efficient and high-quality manner. We are committed to the development and commercialization of three oncology assets discovered by Zentalis (ZN-c3, ZN-c5, ZN-d5) in China. At the same time, we continue to discover and identify molecules that are synergistic with the current assets in our pipeline. We believe Zentera has the potential to become a leading biopharmaceutical company providing patients with first-class cancer drugs.